Compare
Femasys Inc vs Vycor Medical Inc vs EBR Systems, Inc. vs Nuo Therapeutics, Inc.
| Latest fiscal year | Femasys Inc FEMY | Vycor Medical Inc VYCO | EBR Systems, Inc. NONE. | Nuo Therapeutics, Inc. AURX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.29M | $1.86M | $1.62M | $3.31M |
| Revenue growth (YoY) | +40.8% | +17.2% | n/a | +142.7% |
| Gross margin | 62.0% (computed) | 83.8% | 30.3% | 66.9% |
| Operating margin | -767.0% | 1.8% | n/m | -76.0% |
| Net margin | -812.3% | -3.9% | n/m | -75.8% |
| Net income | -$18.63M | -$72.4K | -$48.76M | -$2.51M |
| EPS (Diluted) | -$0.47 | -$0.01 | -$0.12 | n/a |
| Operating cash flow | -$18.69M | -$13.5K | -$53.19M | -$865.0K |
| Free cash flow | -$19.22M | -$18.7K | -$56.88M | -$1.14M |
| Cash & equivalents | $9.27M | $87.0K | $5.79M | $548.9K |
| Total assets | $20.72M | $830.4K | $97.23M | $1.85M |
| Total liabilities | $14.85M | $4.92M | $71.64M | $2.80M |
| Shareholders' equity | $5.87M | -$4.09M | $25.59M | -$956.6K |
| Return on year-end equity | -317.4% | n/a | -190.6% | n/a |
| Shares outstanding | 59.60M | 33.37M | 450.26M | 48.18M |
Revenue, most recent five fiscal years
| Fiscal year | Femasys Inc | Vycor Medical Inc | EBR Systems, Inc. | Nuo Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $2.29M Ended 2025-12-31 | $1.86M Ended 2025-12-31 | $1.62M Ended 2025-12-31 | $3.31M Ended 2025-12-31 |
| 1 year earlier | $1.63M Ended 2024-12-31 | $1.59M Ended 2024-12-31 | n/a | $1.37M Ended 2024-12-31 |
| 2 years earlier | $1.07M Ended 2023-12-31 | $1.46M Ended 2023-12-31 | n/a | $608.5K Ended 2023-12-31 |
| 3 years earlier | $1.21M Ended 2022-12-31 | $1.22M Ended 2022-12-31 | n/a | $112.2K Ended 2022-12-31 |
| 4 years earlier | $1.18M Ended 2021-12-31 | $1.39M Ended 2021-12-31 | n/a | $0 Ended 2021-12-31 |